You searched for "Immunotherapy"
Immunotherapy in renal cancer
Renal cell carcinoma (RCC) is the sixth most common solid organ cancer in the UK. In 2018, there were 403,262 people diagnosed worldwide with the disease (2.2% of all cancer cases), and it accounted for 175,098 deaths in total (1.8%...Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...
BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...Recent developments in bladder cancer
There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...BLADDR 2019: Global Congress on Bladder Cancer
“Good talkers are only found in Paris” François Villon used to say. Boy, was he right, certainly on 25-26 October 2019, when international multidisciplinary top experts come together at the Global Congress on Bladder Cancer (BLADDR) in Paris to discuss...
